论文部分内容阅读
重视高血压治疗中的经济学评价,对利用我国有限的卫生资源来遏制高血压对人民群众的危害有着重要的现实意义。药物经济学对于药物治疗的成本和治疗的结果给予同样的关注。因为治疗高血压的费用,不仅涉及药物价格,还包括患者的危险水平,降压疗效和对临床终点事件的影响,以及治疗的依从性和安全性。因此药物经济学更强调整体成本和价-效比。低危病人,若非药价低廉,治疗的价-效比不够理想。而在高危的患者,价-效比越小越经济而不是药费越便宜越好。
Attention should be paid to the economic evaluation of hypertension treatment, which is of great practical significance for using the limited health resources in our country to curb the harm of hypertension to the people. Pharmacoeconomics gives the same attention to the cost of medication and the outcome of treatment. Because the cost of treating high blood pressure, not only the price of the drug, but also the patient’s risk level, antihypertensive efficacy and impact on clinical endpoints, and adherence and safety of treatment. Pharmacoeconomics therefore emphasizes overall costs and price-effectiveness. Low-risk patients, if non-drug prices, the treatment of the price - efficiency is not ideal. In high-risk patients, the lower the price-effectiveness ratio, the more economical rather than less expensive the better.